Joint Formulary & PAD

Filgotinib - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Filgotinib
Indication :
Inflammatory bowel disease
Group Name :
Keywords :
Ulcerative colitis, UC, high cost immunomodulator, Sequential use of biologic medicines , JAK inhibitor, Janus Kinase, Jakinib
Brand Names Include :
Jyseleca
Important Information :
Ulcerative colitis - adults only
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Other Indications

Below are listed other indications that Filgotinib is used to treat.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found on the IBD guidelines page.

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the use of filgotinib for treating moderately to severely active ulcerative colitis in line with NICE TA792.

Filgotinib will be given a RED traffic light status. Prescribing will be by hospital specialists only using Blueteq forms for initiation & continuation

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.